Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Amylyx Pharmaceuticals, Inc.AMLX · Entity 259 | Director | October 05, 2026 | October 07, 2026 |
| Aurinia Pharmaceuticals Inc.AUPH · Entity 4463 | Director | May 18, 2023 | May 23, 2023 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC.CRL · Entity 3398 | Director | May 07, 2021 | May 10, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Amylyx Pharmaceuticals, Inc.
Report date October 05, 2026 · Filed October 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 782,881 |
Reported balance
After 2026-10-05 transaction · row 1
1 source rowRow 1 · 2026-10-05 · Sale · Disposed 30,000 · Balance 782,881 F1: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on April 28, 2026. F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.36 to $28.05. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on April 28, 2026.
F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.36 to $28.05. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Aurinia Pharmaceuticals Inc.
Report date May 18, 2023 · Filed May 23, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 78,733 |
Reported balance
After 2023-05-18 transaction · row 1
1 source rowRow 1 · 2023-05-18 · Exercise / conversion · Acquired 8,733 · Balance 78,733 F1: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of Issuer Common Stock. The RSUs have no expiration date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-05-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-05-18 · Exercise / conversion · Disposed 8,733 · Balance 0 F1: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of Issuer Common Stock. The RSUs have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of Issuer Common Stock. The RSUs have no expiration date.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Report date May 07, 2021 · Filed May 10, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 29,079 |
Ending reported balance
After 2021-05-07 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2021-05-07 · Grant · Acquired 355 · Balance 28,772 F1: The unvested restricted stock units vest upon the earlier of 5/7/2022 or the business day prior to the Company's next annual meeting of shareholders. Row 2 · 2021-05-07 · Grant · Acquired 307 · Balance 29,079 F2: The grant was made in lieu of director service fees for the term commencing May 5, 2021. The restricted stock units vest upon the earlier of 5/7/2022, or the business day prior to the Company's next annual meeting of shareholders. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $342.55 · Expires 2031-05-07 | Direct | 1,151 |
Reported balance
After 2021-05-07 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-05-07 · Grant · Acquired 1,151 · Balance 1,151 F3: The Stock Options become exercisable upon the earlier of 5/7/2022 or the business day prior to the Company's next annual meeting of shareholders. |
| Common StockSEC Table I · non-derivative | IndirectHeld By Spouse | 1,000 |
Reported balance
Holding disclosure · report date 2021-05-07 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 1,000 |
Filing footnotes · ownership attribution and instrument terms
F1: The unvested restricted stock units vest upon the earlier of 5/7/2022 or the business day prior to the Company's next annual meeting of shareholders.
F2: The grant was made in lieu of director service fees for the term commencing May 5, 2021. The restricted stock units vest upon the earlier of 5/7/2022, or the business day prior to the Company's next annual meeting of shareholders.
F3: The Stock Options become exercisable upon the earlier of 5/7/2022 or the business day prior to the Company's next annual meeting of shareholders.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 05, 2026 Filed Oct 7, 2026 20:00 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | SaleCommon Stock | 30,000 | $27.70 | $830,904.00 |
DisclosureSEC source: 0001193125-26-416950 · ownership.xml · nonDerivative · entry 1 MILNE GEORGE M JR · CIK 0001179552 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 782,881 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on April 28, 2026. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.36 to $28.05. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| June 04, 2026 Filed Jun 8, 2026 20:00 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | GrantStock Option (right to buy) · Derivative | 24,372 | $0.00 Strike: $14.31 | $0.00 |
DisclosureSEC source: 0001193125-26-261638 · ownership.xml · derivative · entry 1 MILNE GEORGE M JR · CIK 0001179552 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,372 Underlying: Common Stock · 24,372 shares Expires 2036-06-03 F1 · derivative.exercise_date: The shares subject to this option shall vest in full upon the earlier of (i) June 4, 2027 or (ii) the date of the next annual meeting, subject to the Reporting Person's continuous service to the Issuer through such vesting date. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 21:08 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | GiftCommon Stock | 17,780 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-012921 · ownership.xml · nonDerivative · entry 1 MILNE GEORGE M JR · CIK 0001179552 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 812,881 F1 · kind: Represents a bona fide gift for no consideration. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 20:06 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $5.05 | $0.00 |
DisclosureSEC source: 0000950170-25-083713 · ownership.xml · derivative · entry 1 MILNE GEORGE M JR · CIK 0001179552 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2035-06-04 F1 · derivative.exercise_date: The shares subject to this option shall vest in full upon the earlier of (i) June 5, 2026 or (ii) the date of the next annual meeting, subject to the Reporting Person's continuous service to the Issuer through such vesting date. Read SEC document |
| January 24, 2025 Filed Jan 28, 2025 21:55 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | GiftCommon Stock | 27,910 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-009913 · ownership.xml · nonDerivative · entry 1 MILNE GEORGE M JR · CIK 0001179552 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 830,661 F1 · kind: Represents a bona fide gift for no consideration. F2 · shares: These shares of common stock remain subject to a lock-up agreement pursuant to which they cannot be sold prior to March 11, 2025 without the consent of Leerink Partners LLC, subject to certain exceptions. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 23:26 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | PurchaseCommon Stock | 100,000 | $2.20 | $219,800.00 |
DisclosureSEC source: 0000950170-24-104186 · ownership.xml · nonDerivative · entry 1 MILNE GEORGE M JR · CIK 0001179552 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 858,571 F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $2.14 to $2.235. Full information regarding the number of shares purchased at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| June 06, 2024 Filed Jun 7, 2024 20:44 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $1.76 | $0.00 |
DisclosureSEC source: 0000950170-24-070778 · ownership.xml · derivative · entry 1 MILNE GEORGE M JR · CIK 0001179552 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2034-06-05 F1 · derivative.exercise_date: The shares subject to this option shall vest in full upon the earlier of (i) June 6, 2025 or (ii) the date of the next annual meeting, subject to the Reporting Person's continuous service to the Issuer through such vesting date. Read SEC document |
| January 25, 2024 Filed Jan 29, 2024 21:38 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | GiftCommon Stock | 9,100 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-008347 · ownership.xml · nonDerivative · entry 1 MILNE GEORGE M JR · CIK 0001179552 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 758,571 Read SEC document |
| January 16, 2024 Filed Jan 18, 2024 21:50 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | GiftCommon Stock | 94,350 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-005437 · ownership.xml · nonDerivative · entry 1 MILNE GEORGE M JR · CIK 0001179552 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 767,671 Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 23:46 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | GrantStock Option (right to buy) · Derivative | 16,985 | $0.00 Strike: $26.25 | $0.00 |
DisclosureSEC source: 0000899243-23-015410 · doc4.xml · derivative · entry 1 MILNE GEORGE M JR · CIK 0001179552 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,985 Underlying: Common Stock · 16,985 shares Expires 2033-06-08 F1 · derivative.exercise_date: The shares subject to this option shall vest in full upon the earlier of (i) June 8, 2024 or (ii) the date of the next annual meeting, subject to the Reporting Person's continuous service to the Issuer through such vesting date. Read SEC document |
| May 18, 2023 Filed May 23, 2023 21:16 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | Exercise / conversionRestricted Stock Units · Derivative | 8,733 | $0.00 | $0.00 |
DisclosureSEC source: 0001600620-23-000019 · wk-form4_1684876599.xml · derivative · entry 2 MILNE GEORGE M JR · CIK 0001179552 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,733 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of Issuer Common Stock. The RSUs have no expiration date. F1 · derivative.expiration_date: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of Issuer Common Stock. The RSUs have no expiration date. Read SEC document |
| May 18, 2023 Filed May 23, 2023 21:16 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | Exercise / conversionCommon Stock | 8,733 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001600620-23-000019 · wk-form4_1684876599.xml · nonDerivative · entry 1 MILNE GEORGE M JR · CIK 0001179552 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,733 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of Issuer Common Stock. The RSUs have no expiration date. Read SEC document |
| March 16, 2023 Filed Mar 21, 2023 00:25 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | SaleCommon Stock | 1,916 | $32.45 | $62,171.71 |
DisclosureSEC source: 0000899243-23-009179 · doc4.xml · nonDerivative · entry 2 MILNE GEORGE M JR · CIK 0001179552 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 862,021 F1 · kind: These sales were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on November 16, 2022. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.30 to $32.93. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| March 16, 2023 Filed Mar 21, 2023 00:25 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | SaleCommon Stock | 33,084 | $31.86 | $1,053,900.75 |
DisclosureSEC source: 0000899243-23-009179 · doc4.xml · nonDerivative · entry 1 MILNE GEORGE M JR · CIK 0001179552 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 863,937 F1 · kind: These sales were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on November 16, 2022. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.30 to $32.29. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 21:29 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | PurchaseCommon Stock | 20,000 | $8.91 | $178,284.00 |
DisclosureSEC source: 0001628280-23-006533 · wf-form4_167813818041525.xml · nonDerivative · entry 1 MILNE GEORGE M JR · CIK 0001179552 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 F1 · price: The price in column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $8.86 to $8.97, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| December 29, 2022 Filed Feb 14, 2023 21:35 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | GiftCommon Stock | 13,800 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-004990 · doc5.xml · nonDerivative · entry 2 MILNE GEORGE M JR · CIK 0001179552 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 897,021 Read SEC document |
| June 09, 2022 Filed Jun 10, 2022 20:05 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | GrantStock Option (Right to Buy) · Derivative | 19,000 | $0.00 Strike: $13.56 | $0.00 |
DisclosureSEC source: 0000899243-22-021889 · doc4.xml · derivative · entry 1 MILNE GEORGE M JR · CIK 0001179552 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 19,000 shares Expires 2032-06-09 F1 · derivative.exercise_date: This option shall vest in full upon the earlier of (i) June 9, 2023 or (ii) the date of the next annual meeting, all vesting shall cease if the director resigns from the Board or otherwise ceases to service as a director. Read SEC document |
| May 18, 2022 Filed May 20, 2022 20:10 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | GrantStock Option (right to buy) · Derivative | 14,612 | $0.00 Strike: $11.45 | $0.00 |
DisclosureSEC source: 0001628280-22-015035 · wf-form4_165307739688602.xml · derivative · entry 2 MILNE GEORGE M JR · CIK 0001179552 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,612 Underlying: Common Stock · 14,612 shares Expires 2032-05-18 F2 · derivative.exercise_date: The option vests in twelve equal monthly installments commencing on June 18, 2022. Read SEC document |
| May 18, 2022 Filed May 20, 2022 20:10 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | GrantRestricted Stock Unit · Derivative | 8,733 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-015035 · wf-form4_165307739688602.xml · derivative · entry 1 MILNE GEORGE M JR · CIK 0001179552 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,733 Underlying: Common Shares · 8,733 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuers common stock. The RSUs will vest and be delivered to the Reporting Person one year from date of grant. F1 · derivative.exercise_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuers common stock. The RSUs will vest and be delivered to the Reporting Person one year from date of grant. F1 · derivative.expiration_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuers common stock. The RSUs will vest and be delivered to the Reporting Person one year from date of grant. Read SEC document |
| March 04, 2022 Filed Mar 8, 2022 21:06 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | PurchaseCommon Stock | 5,000 | $10.82 | $54,100.00 |
DisclosureSEC source: 0001628280-22-005381 · wf-form4_164677357726147.xml · nonDerivative · entry 1 MILNE GEORGE M JR · CIK 0001179552 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 F1 · price: The price in column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $10.81 to $10.82, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| January 06, 2022 Filed Jan 11, 2022 01:34 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | GrantStock Option (Right to Buy) · Derivative | 8,400 | $0.00 Strike: $19.00 | $0.00 |
DisclosureSEC source: 0000899243-22-001521 · doc4.xml · derivative · entry 2 MILNE GEORGE M JR · CIK 0001179552 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,400 Underlying: Common Stock · 8,400 shares Expires 2032-01-06 F1 · derivative.exercise_date: This option shall vest in full on the date of the Corporation's 2022 Annual Stockholders Meeting, subject to the Reporting Person's continuous service to the Issuer through such vesting date. Read SEC document |
| January 06, 2022 Filed Jan 11, 2022 01:34 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | PurchaseCommon Stock | 26,315 | $19.00 | $499,985.00 |
DisclosureSEC source: 0000899243-22-001521 · doc4.xml · nonDerivative · entry 1 MILNE GEORGE M JR · CIK 0001179552 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,396 Read SEC document |
| January 06, 2022 Filed Feb 14, 2023 21:35 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | ConversionSeries C-2 Preferred Stock · Derivative | 23,212 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-004990 · doc5.xml · derivative · entry 6 MILNE GEORGE M JR · CIK 0001179552 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,212 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering, all shares of Series A, Series B, Series C-1 and Series C-2 Preferred Stock (the "Preferred Stock") automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering, all shares of Series A, Series B, Series C-1 and Series C-2 Preferred Stock (the "Preferred Stock") automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering, all shares of Series A, Series B, Series C-1 and Series C-2 Preferred Stock (the "Preferred Stock") automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Preferred Stock had no expiration date. Read SEC document |
| January 06, 2022 Filed Feb 14, 2023 21:35 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | ConversionSeries C-1 Preferred Stock · Derivative | 19,482 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-004990 · doc5.xml · derivative · entry 5 MILNE GEORGE M JR · CIK 0001179552 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,482 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering, all shares of Series A, Series B, Series C-1 and Series C-2 Preferred Stock (the "Preferred Stock") automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering, all shares of Series A, Series B, Series C-1 and Series C-2 Preferred Stock (the "Preferred Stock") automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering, all shares of Series A, Series B, Series C-1 and Series C-2 Preferred Stock (the "Preferred Stock") automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Preferred Stock had no expiration date. Read SEC document |
| January 06, 2022 Filed Feb 14, 2023 21:35 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | ConversionSeries B Preferred Stock · Derivative | 384,449 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-004990 · doc5.xml · derivative · entry 4 MILNE GEORGE M JR · CIK 0001179552 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 384,449 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering, all shares of Series A, Series B, Series C-1 and Series C-2 Preferred Stock (the "Preferred Stock") automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering, all shares of Series A, Series B, Series C-1 and Series C-2 Preferred Stock (the "Preferred Stock") automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering, all shares of Series A, Series B, Series C-1 and Series C-2 Preferred Stock (the "Preferred Stock") automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Preferred Stock had no expiration date. Read SEC document |
| January 06, 2022 Filed Feb 14, 2023 21:35 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | ConversionSeries A Preferred Stock · Derivative | 262,282 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-004990 · doc5.xml · derivative · entry 3 MILNE GEORGE M JR · CIK 0001179552 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 262,282 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering, all shares of Series A, Series B, Series C-1 and Series C-2 Preferred Stock (the "Preferred Stock") automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering, all shares of Series A, Series B, Series C-1 and Series C-2 Preferred Stock (the "Preferred Stock") automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering, all shares of Series A, Series B, Series C-1 and Series C-2 Preferred Stock (the "Preferred Stock") automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Preferred Stock had no expiration date. Read SEC document |
| January 06, 2022 Filed Feb 14, 2023 21:35 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | ConversionCommon Stock | 689,425 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-004990 · doc5.xml · nonDerivative · entry 1 MILNE GEORGE M JR · CIK 0001179552 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 910,821 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Upon the closing of the Issuer's initial public offering, all shares of Series A, Series B, Series C-1 and Series C-2 Preferred Stock (the "Preferred Stock") automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Preferred Stock had no expiration date. Read SEC document |
| June 14, 2021 Filed Jun 17, 2021 01:20 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | GrantStock Option (right to buy) · Derivative | 31,347 | $0.00 Strike: $12.86 | $0.00 |
DisclosureSEC source: 0001628280-21-012386 · wf-form4_162389281306609.xml · derivative · entry 1 MILNE GEORGE M JR · CIK 0001179552 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,347 Underlying: Stock Option (right to buy) · 31,347 shares Expires 2031-06-14 F1 · derivative.exercise_date: The option vests in twelve equal monthly installments commencing on July 14, 2021. Read SEC document |
| May 07, 2021 Filed May 10, 2021 21:39 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantStock Options (Right to Buy) · Derivative | 1,151 | $0.00 Strike: $342.55 | $0.00 |
DisclosureSEC source: 0001127602-21-016113 · form4.xml · derivative · entry 4 MILNE GEORGE M JR · CIK 0001179552 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,151 Underlying: Common Stock · 1,151 shares Expires 2031-05-07 F3 · shares: The Stock Options become exercisable upon the earlier of 5/7/2022 or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| May 07, 2021 Filed May 10, 2021 21:39 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 307 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-016113 · form4.xml · nonDerivative · entry 2 MILNE GEORGE M JR · CIK 0001179552 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,079 F2 · shares: The grant was made in lieu of director service fees for the term commencing May 5, 2021. The restricted stock units vest upon the earlier of 5/7/2022, or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| May 07, 2021 Filed May 10, 2021 21:39 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 355 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-016113 · form4.xml · nonDerivative · entry 1 MILNE GEORGE M JR · CIK 0001179552 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,772 F1 · shares: The unvested restricted stock units vest upon the earlier of 5/7/2022 or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| March 05, 2021 Filed Mar 9, 2021 21:25 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | PurchaseCommon Stock | 5,000 | $13.00 | $65,000.00 |
DisclosureSEC source: 0001628280-21-004265 · wf-form4_161532509442005.xml · nonDerivative · entry 1 MILNE GEORGE M JR · CIK 0001179552 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.995 to $13.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| March 01, 2021 Filed Mar 2, 2021 21:47 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionStock Options (Right to Buy) · Derivative | 3,530 | $0.00 Strike: $52.29 | $0.00 |
DisclosureSEC source: 0001127602-21-008742 · form4.xml · derivative · entry 4 MILNE GEORGE M JR · CIK 0001179552 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,530 shares Expires 2021-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2021 Filed Mar 2, 2021 21:47 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 3,530 | $290.01 | $1,023,730.01 |
DisclosureSEC source: 0001127602-21-008742 · form4.xml · nonDerivative · entry 2 MILNE GEORGE M JR · CIK 0001179552 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,417 F1 · price: This transaction was executed in multiple trades at prices ranging from $290.00 to $290.175. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 01, 2021 Filed Mar 2, 2021 21:47 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionCommon Stock | 3,530 | $52.29 | $184,583.70 |
DisclosureSEC source: 0001127602-21-008742 · form4.xml · nonDerivative · entry 1 MILNE GEORGE M JR · CIK 0001179552 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,947 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 11, 2020 Filed May 12, 2020 18:23 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantStock Options (Right to Buy) · Derivative | 2,539 | $0.00 Strike: $164.24 | $0.00 |
DisclosureSEC source: 0001127602-20-016255 · form4.xml · derivative · entry 4 MILNE GEORGE M JR · CIK 0001179552 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,539 Underlying: Common Stock · 2,539 shares Expires 2030-05-11 F3 · derivative.exercise_date: The Stock Options become exercisable upon the earlier of 5/11/2021 or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| May 11, 2020 Filed May 12, 2020 18:23 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 639 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-016255 · form4.xml · nonDerivative · entry 2 MILNE GEORGE M JR · CIK 0001179552 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,417 F2 · shares: The grant was made in lieu of director service fees for the term commencing May 6, 2020. The restricted stock units vest upon the earlier of 5/11/2021, or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| May 11, 2020 Filed May 12, 2020 18:23 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 741 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-016255 · form4.xml · nonDerivative · entry 1 MILNE GEORGE M JR · CIK 0001179552 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,778 F1 · shares: The unvested restricted stock units vest upon the earlier of 5/11/2021 or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 15:41 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionStock Options (Right to Buy) · Derivative | 3,140 | $0.00 Strike: $70.29 | $0.00 |
DisclosureSEC source: 0001127602-20-006257 · form4.xml · derivative · entry 6 MILNE GEORGE M JR · CIK 0001179552 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,140 shares Expires 2020-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 15:41 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionStock Options (Right to Buy) · Derivative | 4,030 | $0.00 Strike: $43.39 | $0.00 |
DisclosureSEC source: 0001127602-20-006257 · form4.xml · derivative · entry 5 MILNE GEORGE M JR · CIK 0001179552 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,030 shares Expires 2020-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 15:41 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 7,170 | $176.07 | $1,262,429.79 |
DisclosureSEC source: 0001127602-20-006257 · form4.xml · nonDerivative · entry 3 MILNE GEORGE M JR · CIK 0001179552 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,037 F1 · price: This transaction was executed in multiple trades at prices ranging from $175.70 to $176.30. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 15:41 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionCommon Stock | 3,140 | $70.29 | $220,710.60 |
DisclosureSEC source: 0001127602-20-006257 · form4.xml · nonDerivative · entry 2 MILNE GEORGE M JR · CIK 0001179552 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,207 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 15:41 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionCommon Stock | 4,030 | $43.39 | $174,861.70 |
DisclosureSEC source: 0001127602-20-006257 · form4.xml · nonDerivative · entry 1 MILNE GEORGE M JR · CIK 0001179552 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,067 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 22, 2019 Filed May 23, 2019 17:30 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 812 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-019572 · form4.xml · nonDerivative · entry 2 MILNE GEORGE M JR · CIK 0001179552 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,037 F2 · kind: This grant was made in lieu of director service fees for the term commencing May 21, 2019. The restricted stock units vest upon the earlier of 5/22/2020, or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| May 22, 2019 Filed May 23, 2019 17:30 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 1,882 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-019572 · form4.xml · nonDerivative · entry 1 MILNE GEORGE M JR · CIK 0001179552 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,225 F1 · kind: Consists of 1,882 unvested restricted stock units that vest upon the earlier of 5/22/2020, or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
| February 22, 2019 Filed Feb 25, 2019 15:12 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionStock Options (Right to Buy) · Derivative | 4,540 | $0.00 Strike: $33.93 | $0.00 |
DisclosureSEC source: 0001127602-19-007889 · form4.xml · derivative · entry 4 MILNE GEORGE M JR · CIK 0001179552 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,540 shares Expires 2019-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 22, 2019 Filed Feb 25, 2019 15:12 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 4,540 | $143.00 | $649,220.00 |
DisclosureSEC source: 0001127602-19-007889 · form4.xml · nonDerivative · entry 2 MILNE GEORGE M JR · CIK 0001179552 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,343 Read SEC document |
| February 22, 2019 Filed Feb 25, 2019 15:12 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionCommon Stock | 4,540 | $33.93 | $154,042.20 |
DisclosureSEC source: 0001127602-19-007889 · form4.xml · nonDerivative · entry 1 MILNE GEORGE M JR · CIK 0001179552 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,883 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 03, 2018 Filed Feb 1, 2019 18:08 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GiftCommon Stock | 5,240 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-003337 · form5.xml · nonDerivative · entry 1 MILNE GEORGE M JR · CIK 0001179552 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,343 Read SEC document |
| May 14, 2018 Filed May 15, 2018 20:14 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 839 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-017521 · form4.xml · nonDerivative · entry 3 MILNE GEORGE M JR · CIK 0001179552 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,583 F2 · kind: This grant was made in lieu of director service fees for the term commencing May 8, 2018. The restricted stock units vest upon the earlier of 5/14/2019 or the business day prior to the Company's next annual meeting of shareholders. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.